Answers are grounded in this paper and cite their sources.
Preeclampsia complicates 2–8% of pregnancies worldwide. HELLP syndrome is often considered a severe form of preeclampsia but can also present independently. These two conditions may have serious long-term consequences to the fetus and the mother, such as preterm birth or permanent organ damage to the mother. Growing evidence suggests that part of patients suffering from severe preeclampsia/HELLP present also TMA-type disease and may significantly benefit of new specific anti-complement medication to prevent organ damage. 41-year-old primigravida presented severe preeclampsia and HELLP at 34 gestational weeks, with signs of rapidly developing organ (liver) damage and thrombotic microangiopathy. High AST and ALT levels, necrosis in liver tissue, and poor portal vein blood flow in ultrasound indicated severe liver damage. Red cell fragmentation and thrombocytopenia indicated thrombotic microangiopathy and together with organ damage and signs of abnormal complement consumption led to the diagnosis of pregnancy-associated TMA. The patient was successfully treated with anti-complement medication (eculizumab) on the first postpartum day leading to rapid clinical recovery. Part of patients suffering from severe preeclampsia and HELLP present also thrombotic microangiopathy associated with disturbances in the complement function and may benefit from targeted anti-complement therapy.
No takes yet. Share an insight, caveat, or question.
Korkalainen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: